A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

PURPOSE: To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Between 2017 and 2019, histologically confirmed patients with mCRC (n = 442) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, He, Ming-Ming, Xiao, Jian, Zhang, Yan-Qiao, Yuan, Xiang-Lin, Fang, Wei-Jia, Zhang, Yan, Wang, Wei, Hu, Xiao-Hua, Ma, Zhi-Gang, Yao, Yi-Chen, Zhuang, Zhi-Xiang, Zhou, Fu-Xiang, Ying, Jie-Er, Yuan, Ying, Zou, Qing-Feng, Guo, Zeng-Qing, Wu, Xiang-Yuan, Jin, Ying, Mai, Zong-Jiong, Wang, Zhi-Qiang, Qiu, Hong, Guo, Ying, Shi, Si-Mei, Chen, Shuang-Zhen, Luo, Hui-Yan, Zhang, Dong-Sheng, Wang, Feng-Hua, Li, Yu-Hong, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527503/
https://www.ncbi.nlm.nih.gov/pubmed/35929990
http://dx.doi.org/10.1158/1078-0432.CCR-22-0655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527503/
https://www.ncbi.nlm.nih.gov/pubmed/35929990
http://dx.doi.org/10.1158/1078-0432.CCR-22-0655

Ejemplares similares